ARCII: Nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy (CRT) in locally-advanced pancreatic cancer (LAPC)–mechanism and clinical outcomes
Background: In LAPC, additional benefit of CRT over chemotherapy is uncertain. Optimising local therapy for a subset that never develops distant disease may prolong survival. Nelfinavir is thought to enhance radiosensitivity through hypoxia reduction by increasing tumour blood flow. Methods: A non-r...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Conference item |
| Published: |
American Society of Clinical Oncology
2017
|